Questions and answers

Question reference: S6W-38385

Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
Date lodged: Thursday, 05 June 2025
Current Status: Answered by Neil Gray on 13 June 2025

To ask the Scottish Government what its position is on whether the inclusion of a right to palliative care is within the scope of the Assisted Dying for Terminally Ill Adults (Scotland) Bill.

The Assisted Dying for Terminally Ill Adults (Scotland) Bill was introduced to the Scottish Parliament on 27 March 2024 by Liam McArthur MSP (Liberal Democrats). As such, this is a Member's Bill, not a Scottish Government Bill.

As with all Bills, at Stage 2 of the Bill’s passage through Parliament it is for the Convener of the lead Committee to make a decision on the admissibility of any amendment put forward.

At Stage 3, it would be for the Scottish Parliament’s Presiding Officer to make decisions on admissibility.

Question reference: S6W-38120

Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
Date lodged: Monday, 02 June 2025
Current Status: Answered by Jenni Minto on 13 June 2025

To ask the Scottish Government what medical pathways are available to those experiencing symptoms associated with topical steroid withdrawal.

The medicines regulatory body, the MHRA, has issued regulatory action on labelling of topical steroids with their potencies, so that prescribers and patients can have informed discussions about the length of treatment of these products and associated risks and benefits.

The Scottish Government encourages individuals to review their treatment plans with their healthcare professionals at least annually, however they can be reviewed more frequently, since reactions can occur within a short timeframe requiring a more urgent review. Specialist dermatology advice and assessment is available through referral by the GP where required.

Question reference: S6W-38119

Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
Date lodged: Monday, 02 June 2025
Current Status: Answered by Jenni Minto on 13 June 2025

To ask the Scottish Government what action it is taking to support people who are reporting topical steroid withdrawal.

In partnership with NHS Scotland colleagues, the Scottish Government are developing tools to support GP practices to proactively identify people on topical steroids so that their treatment can be reviewed.

We have cascaded the medicines regulatory body’s updated safety alert, new labelling information and revised patient safety leaflet to prescribers through our established clinical networks to further raise awareness.

Question reference: S6W-38147

Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
Date lodged: Monday, 02 June 2025
Current Status: Answered by Jenni Minto on 13 June 2025

To ask the Scottish Government whether it will provide an update on its discussions with NHS Greater Glasgow and Clyde on improving waiting times for ovarian cancer surgery.

Question reference: S6W-38384

Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
Date lodged: Thursday, 05 June 2025
Current Status: Answered by Neil Gray on 13 June 2025

To ask the Scottish Government whether it plans to engage in the development of amendments to the Assisted Dying for Terminally Ill Adults (Scotland) Bill.

The Scottish Government is currently considering its position on the Assisted Dying for Terminally Ill Adults (Scotland) Bill moving forward, in light of Parliament’s decision to support the general principles of the Bill. In doing so, we will be taking care to ensure that any future steps are informed, balanced and respectful of the views expressed across the Chamber and the country. As part of this, we are carefully reflecting on the conclusions of the Health, Social Care and Sport Committee in their Stage 1 report.

Question reference: S6W-38146

Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
Date lodged: Monday, 02 June 2025
Current Status: Answered by Jenni Minto on 13 June 2025

To ask the Scottish Government what steps it is taking to ensure that everyone diagnosed with ovarian cancer is able to access ovarian cancer surgery regardless of where they live.

NHS Boards continue to undertake improvement work to ensure that women diagnosed with ovarian cancer can access surgery. The Scottish Government continues to seek regular updates on progress and to work with them to improve overall care for patients with ovarian cancer regardless of where they live.

Further to this, Scottish Government has provided £106 million planned care funding in 2025/26 across NHS Scotland, with £14.23 million of this directed towards Cancer Waiting Times.

This is all part of our programme to drive up productivity and tackle waiting lists, supported by the Centre for Sustainable Delivery (CfSD). Together, our actions will further enable NHS Scotland to maximise capacity, build greater resilience and deliver year-on-year reductions in the number of patients who have waited too long for treatment.

Question reference: S6W-38383

Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
Date lodged: Thursday, 05 June 2025
Current Status: Answered by Neil Gray on 13 June 2025

To ask the Scottish Government what assessment it has made of the potential cost of implementing the provisions in the Assisted Dying for Terminally Ill Adults (Scotland) Bill, and when it will report on its assessment of the potential (a) cost of, (b) practicality of and (c) legal issues arising from implementing the provisions in the Bill.

The Assisted Dying for Terminally Ill Adults (Scotland) Bill was introduced to the Scottish Parliament on 27 March 2024 by Liam McArthur MSP (Liberal Democrats). As such, this is a Member's Bill, not a Scottish Government Bill.

Alongside the Bill, Mr McArthur submitted a Financial Memorandum, setting out an assessment of the projected costs of implementing the Bill. He also wrote to the Health, Social Care and Sport Committee on 17 June 2024, and again on 14 October 2024, to provide updates to the figures in the Financial Memorandum.

A Scottish Government memorandum was provided to the Health, Social Care and Sport Committee on 30 September 2024. This advised that the Scottish Government considered that the costs provided by the member responsible for the Bill were likely to be underestimates. This same memorandum also set out the Scottish Government’s view that the Bill, as introduced, is outside of the legislative competence of the Scottish Parliament, and that the Scottish Government would be taking a neutral position on the Bill.

A further letter was sent to the Committee on 27 February 2025, following the Scottish Government’s oral evidence session, to provide estimates of the costs associated with providing initial and refresher training to NHS staff. This noted that all cost estimates provided at this stage are purely indicative, and that this is something that will need to be kept under careful review as the Bill moves through the Parliamentary process.

Significant issues were raised about various aspects of the Bill in the Committee’s Stage 1 report, and during the Stage 1 debate. As highlighted in the Stage 1 report, the Committee made a number of recommendations in relation to the detail of the Bill including about areas for further debate and potential amendment. As such, we are considering our own position moving forward, in light of Parliament's decision to support the general principles of the Bill, and we will be paying close attention to any amendments put forward by non-Government ��˿�� to consider the practical, financial and legal implications of these.

Question reference: S6W-38118

Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
Date lodged: Monday, 02 June 2025
Current Status: Answered by Neil Gray on 9 June 2025

To ask the Scottish Government whether it currently funds any research into topical steroid withdrawal, and, if this is not the case, whether it plans to do so.

The Scottish Government’s Chief Scientist Office (CSO) supports open competitive grant and fellowship schemes for applied health research in Scotland across a wide remit that is inclusive of consideration of applications for funding for research relating to skin conditions such as topical steroid withdrawal. Applications submitted to these schemes are assessed through independent expert peer-review with funding recommendations made by independent expert committees. No projects for topical steroid withdrawal are currently being funded. CSO also invests in NHS Research Scotland to support NHS Boards host and participate in public, charity, and industry sector funded clinical studies and trials. This includes a Dermatology Research Network to support the delivery of clinical research on skin conditions. While a number of clinical studies of treatments for skin conditions are being supported, none relate specifically to topical steroid withdrawal.

Question reference: S6W-37919

Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
Date lodged: Wednesday, 28 May 2025
Current Status: Answered by Neil Gray on 5 June 2025

To ask the Scottish Government how many GP practices are not currently participating in the national digital dermatology pathway.

Question reference: S6O-04791

Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
Date lodged: Wednesday, 04 June 2025
Current Status: Taken in the Chamber on 12 June 2025

To ask the Scottish Government what its position is on the reasons for there being more private hospital admissions in 2024 than in any previous year on record, according to recent Private Healthcare Information Network data.

��˿��

Chamber and committees